Table 2.
Compound | Concentration μg/ml | UIC2 epitope up-modulation (A) | Doxorubicin efflux inhibition (B) |
RDS 1992 | 25 | NT | + |
50 | + | ++ | |
100 | ++ | NT | |
RDS 1996 | 25 | NT | + |
50 | NT | ++ | |
100 | NT | NT | |
RDS 1997 | 25 | NT | + |
50 | + | ++ | |
100 | ++ | NT | |
RDS 2012 | 25 | NT | + |
50 | + | ++ | |
100 | ++ | NT | |
RDS 2022 | 25 | NT | + |
50 | + | ++ | |
100 | ++ | NT |
A, modulation of UIC2 epitope was studied in CEM-VBL10 cells; B, the effect of IINs on the doxorubicin transport inhibition was analysed in CEM-VBL100 cells; NT, not tested; the + or ++ symbols indicate arbitrary units in measuring and differentiating the level of UIC2 epitope modulation and doxorubicin retention.